Bonanza Creek Energy Target Raised and 4 Stock Analyses Trending Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Bonanza Creek Energy (NYSE:BCEI): Stifel Nicolaus increased their target on Bonanza Creek Energy, as the firm’s analysis of well data led them to raise their outlook for the company’s Niobrara property. The firm maintains a Buy rating on their stock.

Viacom, Inc. (NASDAQ:VIAB): Susquehanna said that if Viacom, Inc.’s ratings improve, they expect their price/earnings multiple to expand. The firm said if the ratings do not improve, the downside in their shares should be limited to $1.00 in stock price. Susquehanna said that comps should get easier until March, so the odds of a turnaround are good as is the risk/reward. Shares are Positive rated with a $63 price target.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Tempur Pedic International Inc. (NYSE:TPX): Stifel Nicolaus believes that Tempur-Pedic International Inc.’s proposed merger with Sealy (NYSE:ZZ) has more plusses than minuses both strategically and financially. The firm thinks the combined company would arguably have the best brands in the sector and they think that the deal will be accretive by about 19% to Tempur Pedic’s 2013 earnings per share estimate. The firm maintains a Buy rating on Tempur Pedic.

Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR): Longbow’s checks indicate that the impact for the  first couple of weeks of October from private label K-Cups was negligible. The firm said that many retailers were not even aware of private label K-Cups and that capacity may not be as great as investors fear. The firm recommends buying shares on the recent sell-off and reiterates their Buy rating and $45 price target.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): After Vertex Pharmaceuticals Incorporated presented key efficacy and safety data for VX809 combination therapy, ThinkEquity believes that the data suggests that the therapy is providing a clinical benefit. The firm thinks that this benefit could be replicated in a Phase III study and they suggest  owning the stock. ThinkEquity maintains a Buy rating on their shares.

Investing Insights: Natural Gas Futures Hit a New High – Coal Surges.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business